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Following the advent of genetic engineering techniques, there has been a sea-change in how the 
production of vaccines may be achieved. It is now possible to put any isolated and defined gene from any 
organism into any other organism  or even the same organism but under the control of other parts of that 
genome. This is reflected in the present issue of the Procedia in Vaccinology.  
One the one hand we note the use of an appropriately defective Salmonella bacterium as a vector for an 
Influenza vaccine. This should enable this vaccine to be given by mouth which gets round the much 
disliked method of vaccination by needle injection. This genetic modification of a bacterium is also the 
method chosen to make more effective vaccines for piglets. Here the genetic modification is based on the 
insertion of genes that are directed at enhancing the quality and quantity of the immune response. Thus, 
genes for Interleukines -4 and -6 are used either together or in conjunction with a polynucleotide based on 
repeated motifs of CpG all encapsulated in Chitosan which itself may enhance the immune response as 
well as increase vaccine stability and shelf-life. In addition to the enhancement of adjuvanticity by genetic 
means, new chemical formulations may also be added to vaccines to bring about this necessary increase 
in potency. This issue of the Procedure has papers that report such advances with regard to the vaccines 
for Newcastle Disease and Porcine CircoVirus 2 (PCV2) in poultry and swine respectively.  
It is noteworthy that apart from the USA and Europe, other countries are realising the cost-effectiveness 
of providing health-care to humans and animals via the agency of vaccines. In this issue we have papers 
from China, Russia, Ethiopia and Thailand  in addition to France and Australia. The production of a cell-
culture based vaccine for Rabies in Ethiopia represents a step forward in technological proficiency and it 
is encouraging to note progress in the control of the infection of chickens by Campylobacter.  
We have a serious issue in the development of some new vaccines in that we do not always know with 
both precision and high levels of confidence how we might determine the efficacy of a vaccine by 
measuring a parameter that relates to the immune system. One of the presented papers seeks to increase 
our understandings in the area of a determination of the response of humans to vaccines containing live 
plague bacilli.  
And finally we report on an update of developments in the HIV/AIDS vaccine area following the 
publication of the results of the RV144 trial. 
In sum, this Procedia covers developments in several areas of keen interest to all those who are seeking to 
advance the field of vaccines and vaccination.    
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